Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 70
- Registration Number
- NCT02350673
- Locations
- 🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇺🇸SCRI-Tennessee Oncology, Nashville, Tennessee, United States
A Study of the Effect of RG1662 on Metformin in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 17
- Registration Number
- NCT02342925
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 212
- Registration Number
- NCT02340234
- Locations
- 🇨🇦
The Centre for Dermatology, Richmond Hill, Ontario, Canada
🇩🇪Universitätsklinik Bonn, Bonn, Germany
🇫🇮Helsinki University Central Hospital; Skin & Allergy Hospital, Helsinki, Finland
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 631
- Registration Number
- NCT02340221
- Locations
- 🇦🇹
Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I, Graz, Austria
🇦🇹Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Wien, Austria
🇧🇬Complex Oncological Center - Plovdiv, EOOD, Plovdiv, Bulgaria
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
- Conditions
- B-Cell Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2015-01-12
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT02336048
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain
🇪🇸Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain
🇮🇹Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Sant'Andrea Delle Fratte (PG), Umbria, Italy
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 149
- Registration Number
- NCT02324257
- Locations
- 🇺🇸
Cedars Sinai Medical Center; Samuel-Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇪🇸START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
🇺🇸Stanford University, Palo Alto, California, United States
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 169
- Registration Number
- NCT02322814
- Locations
- 🇺🇸
Cancer Treatment Centers of America, Newnan, Georgia, United States
🇦🇺St John of God Murdoch Hospital; Oncology West, Murdoch, Western Australia, Australia
🇧🇪Clinique Edith Cavell, Bruxelles, Belgium
Observational Safety Study of Rituximab in Patients Diagnosed With Rheumatoid Arthritis (RA) Who Did Not Respond Adequately to TNF-alpha Blocker
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 209
- Registration Number
- NCT02322801
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 221
- Registration Number
- NCT02323191
- Locations
- 🇺🇸
Dana Farber - Harvard, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center Breast & Imaging Center, New York, New York, United States
🇪🇸Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RO6889678 and the Combination of RO6889678 With Ritonavir in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT02321384
- Locations
- 🇳🇱
Centre For Human Drug Research; Research, Leiden, Netherlands